结合
瑞巴派特
分泌物
化学
角膜
人造眼泪
粘蛋白
上皮
杯状细胞
眼药水
眼科
药品
角膜上皮
药理学
细胞
原位
生物物理学
溶解度
眼泪
医学
毒品携带者
细胞生物学
跨细胞
眼病
生物化学
细胞培养
黏膜黏附
结膜
MUC1号
作者
Guanghao Lv,Lei Lei,Xingyi Li,Xingyi Li,Ying Yang,Yunxiao Zou,Siqi Xie,Ling Wang,Xiaoying Liu,Chenhao Li,Haiqi Wang,Xingyi Li,Jiaqing Wang,Jiaqing Wang
标识
DOI:10.1016/j.mtbio.2026.102899
摘要
Rebamipide is effective for dry eye management, but its insolubility limits formulation development. An optimal design is crucial for patient comfort and maximizing bioavailability. Here we covalently conjugate rebamipide with a peptide motif (FFFYpEH) to generate a peptide-drug conjugate that dramatically improves solubility and enables in situ self-assembly. After topical instillation, the conjugate undergoes enzyme-instructed self-assembly, leading to enhanced drug retention (>25 min) on the ocular surface. In vitro , the conjugate stimulates MUC1 secretion in human corneal epithelial cells and MUC5AC secretion in human conjunctival epithelial cells. In a murine dry eye model, the conjugate demonstrates superior therapeutic efficacy over commercial rebamipide eye drops (Mucosta®), as evidenced by significant symptom alleviation, enhanced corneal epithelial repair, restored tear secretion, and increased conjunctival goblet cell density. Relative to the 14-day non-intervention, treatment of the conjugate results in a threefold increase in corneal epithelium thickness, achieving normal levels. Tear secretion rises nearly fivefold, and conjunctival goblet cell density triples, reaching values comparable to a healthy cornea. Overall, this work addresses the limitations of existing drugs by developing a strategy that not only enhances drug solubility but also promotes ocular retention through in situ self-assembly, thereby offering a promising clinical solution for dry eye management.
科研通智能强力驱动
Strongly Powered by AbleSci AI